Dr. Paul Hofman, Laboratory of Clinical and Experimental Pathology, Nice Hospital, France.
“We can get results quickly and the report is easy to read”
Dr. Paul Hofman is Professor of Pathology at the Nice Sophia Antipolis University, France. He heads the Laboratory of Clinical and Experimental Pathology, which focusses on research into the treatment and prevention of lung cancer.
In this video he talks about the role that NGS can play in a combinatorial approach to lung cancer research, and how the GeneReader NGS System is helping his lab to gain cancer insights.
Andreas Bösl, Head of Molecular Diagnostics, State Hospital Feldkirch, Austria.
“We get 100% concordance with the NGS System”
Andreas Bösl works in the Institute of Pathology in Feldkirch, Austria. Here he talks about his verification study of the GeneReader NGS System and GeneRead AIT Panel for detection of cancer biomarkers in FFPE and liquid biopsy tumor samples.
Dr. Yassmine Akkari, Legacy Health, Portland, Oregon
“We can do something very complex in a very simple manner…”
Dr. Akkari is board-certified in clinical cytogenetics, medical genetics and molecular genetics and has extensive experience working in clinical genetics and genomics. She is Scientific Director of Cytogenetics and Technical Director of Molecular Pathology at Legacy Health.
Hear her talk about her experiences as an early adopter of the GeneReader NGS System.
Prof. Kurt Zatloukal, Institute of Pathology, The Medical University of Graz, Austria
“It's not just producing the NGS data, it is really doing the data interpretation…”
Professor Zatloukal focuses on testing new technologies for the processing of biological samples. He also works closely with the Centre for Biomarker Research in Medicine (CBmed), an Austrian competence center developing customized solutions for biomarker research. As one of the first labs to install a GeneReader NGS System, CBmed has been putting the workflow through its paces with a range of oncology sample types.
Hear how Professor Zatloukal's lab is overcoming NGS bottlenecks with the GeneReader NGS System.
Dr. Clara Mayo de las Casas, Pangaea Oncology, Barcelona, Spain
“The final report that we obtained with the GeneReader System is very complete”
Pangaea Oncology provides R&D and molecular diagnostics services in the field of personalized cancer treatment. Their research programs include Biomarker Discovery, Molecular Diagnostics Assays and Drug Development. Dr. Mayo de las Casas' research has focused on analysis of molecular markers with potential future clinical applications in circulating free DNA of cancer patients.
Hear about her experiences with liquid biopsies and the GeneReader NGS System, presented at AMP Global 2017.
Dr. Florian Haller, Professor of the Institute of Pathology, University Hospital of Erlangen
“…a very good sensitivity also with liquid biopsies...”
Dr. Haller is professor of the Institute of Pathology in Erlangen, Germany. Hear him talk about performance of the GeneReader NGS System to analyze liquid biopsy samples.
The GeneReader NGS System is for Research Use Only. Not for use in diagnostic procedures.